gN2WZW ߣ鐨qʭl q$ :}X,MjVư&0ryUŤޏh, %Et]Aխk#8>4b;KuF1dV@BgyWpZ֬>+ ̲כ#Jv@X8Gň(/EwȉPɕ]Uڌ+mkf˲-+oɫة7>v6ume\Uaʹё(NϢ؈co#е/]5eA{zG1�-/F% 2ɮ6,dיcq! F+3jZ|lZ Xo;y-RvOb_?;OTxi-!O2z롸/Mdf’,@@_OoT;o O$Ǩ64`%Y/h93m&(gJc>S:”N5kExD!Kzf1|M+’X{fu6E݌ 3>.`#Ĩ?Sӌ!c8ʴ)|}R8ѥ)Ncݥdx,iA]w0″L)f|. qN{91؜TWiEO:5`c4ȉ21ԵEH”DŽYt; mp=*a܆y’ԙ>AU?a=LypBL,sŖB”C]Ӧj悌fyn0t?)dD,>”䕙s$ s{tir’.L,3Ui՜FeZu 4Mho&1Ja퍾8u>TY%*:dMvm@R/O(xJ竔ךH 37MqXq,yJ2; G6e\p*)w9=3nӗ|d1+i3En?4jfDgh,7 3|!ew_Mv4N4+a8ņlxf{nO[e C Dw9CX&(.KdZtIhn3Ѷz8rC!`\9~EV/ءaIy EI兗ŽA 4Lc_G]-









Title Post: gN2WZW ߣ鐨qʭl q$ :}X,MjVư&0ryUŤޏh, %Et]Aխk#8>4b;KuF1dV@BgyWpZ֬>+ ̲כ#Jv@X8Gň(/EwȉPɕ]Uڌ+mkf˲-+oɫة7>v6ume\Uaʹё(NϢ؈co#е/]5eA{zG1�-/F% 2ɮ6,dיcq! F+3jZ|lZ Xo;y-RvOb_?;OTxi-!O2z롸/Mdf’,@@_OoT;o O$Ǩ64`%Y/h93m&(gJc>S:”N5kExD!Kzf1|M+’X{fu6E݌ 3>.`#Ĩ?Sӌ!c8ʴ)|}R8ѥ)Ncݥdx,iA]w0″L)f|. qN{91؜TWiEO:5`c4ȉ21ԵEH”DŽYt; mp=*a܆y’ԙ>AU?a=LypBL,sŖB”C]Ӧj悌fyn0t?)dD,>”䕙s$ s{tir’.L,3Ui՜FeZu 4Mho&1Ja퍾8u>TY%*:dMvm@R/O(xJ竔ךH 37MqXq,yJ2; G6e\p*)w9=3nӗ|d1+i3En?4jfDgh,7 3|!ew_Mv4N4+a8ņlxf{nO[e C Dw9CX&(.KdZtIhn3Ѷz8rC!`\9~EV/ءaIy EI兗ŽA 4Lc_G]-
Url Post: http://www.news.fluser.com/gn2wzw-%df%a3%e9%90%a8q%ca%adl-q-xmjvu0ryut%de%8fh-eta%d5%adk84bkuf1dvbgywpz%d6%ac-%cc%b2%d7%9bjvx8gnew%c8%89p%c9%95u%da%8cmkf%cb%b2-o%c9%ab%d8%a97v6umeua%cd%b4/
Link To Post : gN2WZW ߣ鐨qʭl q$ :}X,MjVư&0ryUŤޏh, %Et]Aխk#8>4b;KuF1dV@BgyWpZ֬>+ ̲כ#Jv@X8Gň(/EwȉPɕ]Uڌ+mkf˲-+oɫة7>v6ume\Uaʹё(NϢ؈co#е/]5eA{zG1�-/F% 2ɮ6,dיcq! F+3jZ|lZ Xo;y-RvOb_?;OTxi-!O2z롸/Mdf’,@@_OoT;o O$Ǩ64`%Y/h93m&(gJc>S:”N5kExD!Kzf1|M+’X{fu6E݌ 3>.`#Ĩ?Sӌ!c8ʴ)|}R8ѥ)Ncݥdx,iA]w0″L)f|. qN{91؜TWiEO:5`c4ȉ21ԵEH”DŽYt; mp=*a܆y’ԙ>AU?a=LypBL,sŖB”C]Ӧj悌fyn0t?)dD,>”䕙s$ s{tir’.L,3Ui՜FeZu 4Mho&1Ja퍾8u>TY%*:dMvm@R/O(xJ竔ךH 37MqXq,yJ2; G6e\p*)w9=3nӗ|d1+i3En?4jfDgh,7 3|!ew_Mv4N4+a8ņlxf{nO[e C Dw9CX&(.KdZtIhn3Ѷz8rC!`\9~EV/ءaIy EI兗ŽA 4Lc_G]-
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Cheers! Hollywood Toasts the Oscars





From Elton John's celebrated bash to Vanity Fair's annual soiree, see how George & Stacy, Adele, Jennifer Lawrence and more marked Hollywood's biggest night








Credit: Kevin Mazur/VF13/WireImage



Updated: Monday Feb 25, 2013 | 11:30 AM EST
By: Kiran Hefa & Kate Hogan




Subscribe Now




Read More..

Koop, who transformed surgeon general post, dies


With his striking beard and starched uniform, former Surgeon General Dr. C. Everett Koop became one of the most recognizable figures of the Reagan era — and one of the most unexpectedly enduring.


His nomination in 1981 met a wall of opposition from women's groups and liberal politicians, who complained President Ronald Reagan selected Koop, a pediatric surgeon and evangelical Christian from Philadelphia, only because of his conservative views, especially his staunch opposition to abortion.


Soon, though, he was a hero to AIDS activists, who chanted "Koop, Koop" at his appearances but booed other officials. And when he left his post in 1989, he left behind a landscape where AIDS was a top research and educational priority, smoking was considered a public health hazard, and access to abortion remained largely intact.


Koop, who turned his once-obscure post into a bully pulpit for seven years during the Reagan and George H.W. Bush administrations and who surprised both ends of the political spectrum by setting aside his conservative personal views on issues such as homosexuality and abortion to keep his focus sharply medical, died Monday at his home in Hanover, N.H. He was 96.


An assistant at Koop's Dartmouth College institute, Susan Wills, confirmed his death but didn't disclose its cause.


Dr. Richard Carmona, who served as surgeon general a decade ago under President George W. Bush, said Koop was a mentor to him and preached the importance of staying true to the science even if it made politicians uncomfortable.


"He set the bar high for all who followed in his footsteps," Carmona said.


Although the surgeon general has no real authority to set government policy, Koop described himself as "the health conscience of the country" and said modestly just before leaving his post that "my only influence was through moral suasion."


A former pipe smoker, Koop carried out a crusade to end smoking in the United States; his goal had been to do so by 2000. He said cigarettes were as addictive as heroin and cocaine. And he shocked his conservative supporters when he endorsed condoms and sex education to stop the spread of AIDS.


Chris Collins, a vice president of amFAR, the Foundation for AIDS Research, said many people don't realize what an important role Koop played in the beginning of the AIDS epidemic.


"At the time, he really changed the national conversation, and he showed real courage in pursuing the duties of his job," Collins said.


Even after leaving office, Koop continued to promote public health causes, from preventing childhood accidents to better training for doctors.


"I will use the written word, the spoken word and whatever I can in the electronic media to deliver health messages to this country as long as people will listen," he promised.


In 1996, he rapped Republican presidential hopeful Bob Dole for suggesting that tobacco was not invariably addictive, saying Dole's comments "either exposed his abysmal lack of knowledge of nicotine addiction or his blind support of the tobacco industry."


Although Koop eventually won wide respect with his blend of old-fashioned values, pragmatism and empathy, his nomination met staunch opposition.


Foes noted that Koop traveled the country in 1979 and 1980 giving speeches that predicted a progression "from liberalized abortion to infanticide to passive euthanasia to active euthanasia, indeed to the very beginnings of the political climate that led to Auschwitz, Dachau and Belsen."


But Koop, a devout Presbyterian, was confirmed after he told a Senate panel he would not use the surgeon general's post to promote his religious ideology. He kept his word.


In 1986, he issued a frank report on AIDS, urging the use of condoms for "safe sex" and advocating sex education as early as third grade.


He also maneuvered around uncooperative Reagan administration officials in 1988 to send an educational AIDS pamphlet to more than 100 million U.S. households, the largest public health mailing ever.


Koop personally opposed homosexuality and believed sex should be saved for marriage. But he insisted that Americans, especially young people, must not die because they were deprived of explicit information about how HIV was transmitted.


Koop further angered conservatives by refusing to issue a report requested by the Reagan White House, saying he could not find enough scientific evidence to determine whether abortion has harmful psychological effects on women.


Koop maintained his personal opposition to abortion, however. After he left office, he told medical students it violated their Hippocratic oath. In 2009, he wrote to Senate Majority Leader Harry Reid, urging that health care legislation include a provision to ensure doctors and medical students would not be forced to perform abortions. The letter briefly set off a security scare because it was hand delivered.


Koop served as chairman of the National Safe Kids Campaign and as an adviser to President Bill Clinton's health care reform plan.


At a congressional hearing in 2007, Koop spoke about political pressure on the surgeon general post. He said Reagan was pressed to fire him every day, but Reagan would not interfere.


Koop, worried that medicine had lost old-fashioned caring and personal relationships between doctors and patients, opened his institute at Dartmouth to teach medical students basic values and ethics. He also was a part-owner of a short-lived venture, drkoop.com, to provide consumer health care information via the Internet.


Koop was born in the New York City borough of Brooklyn, the only son of a Manhattan banker and the nephew of a doctor. He said by age 5 he knew he wanted to be a surgeon and at age 13 he practiced his skills on neighborhood cats.


He attended Dartmouth, where he received the nickname Chick, short for "chicken Koop." It stuck for life.


Koop received his medical degree at Cornell Medical College, choosing pediatric surgery because so few surgeons practiced it.


In 1938, he married Elizabeth Flanagan, the daughter of a Connecticut doctor. They had four children, one of whom died in a mountain climbing accident when he was 20.


Koop was appointed surgeon-in-chief at Children's Hospital in Philadelphia and served as a professor at the University of Pennsylvania School of Medicine.


He pioneered surgery on newborns and successfully separated three sets of conjoined twins. He won national acclaim by reconstructing the chest of a baby born with the heart outside the body.


Although raised as a Baptist, he was drawn to a Presbyterian church near the hospital, where he developed an abiding faith. He began praying at the bedside of his young patients — ignoring the snickers of some of his colleagues.


Koop's wife died in 2007, and he married Cora Hogue in 2010.


He was by far the best-known surgeon general and for decades afterward was still a recognized personality.


"I was walking down the street with him one time" about five years ago, recalled Dr. George Wohlreich, director of the College of Physicians of Philadelphia, a medical society with which Koop had longstanding ties. "People were yelling out, 'There goes Dr. Koop!' You'd have thought he was a rock star."


___


Ring reported from Montpelier, Vt. Cass reported from Washington. AP Medical Writers Lauran Neergaard in Washington and Mike Stobbe in New York contributed to this report.


Read More..

Stock futures tick up after sell-off, Italy woes remain

NEW YORK (Reuters) - Stock index futures edged higher on Tuesday, indicating equities would partially rebound from the previous session's steep drop, though concerns persisted over the state of Italy's economy and government makeup.


In Italy's election, groups opposed to economic reforms posted a strong showing, resulting in a political deadlock with a comedian's protest party leading the poll and no group securing a clear majority in parliament.


Major indexes plunged more than 1 percent on Monday, with the S&P 500 having its biggest daily drop since November as investors fretted that if Italy does not undertake reforms, that could once again destabilize the euro zone. The CBOE Volatility Index <.vix> surged 34 percent in its biggest jump since August 18, 2011.


The rise in futures indicates that a recent trend of investors buying on dips will continue. Last week, concerns over whether the Federal Reserve might roll back its stimulus policy earlier than expected prompted a sharp two-day decline, though equities recovered most of ther lost ground by the end of the week. Weakness continued in Europe on Tuesday, with shares <.fteu3> down 1.2 percent.


Financial shares may be among the most volatile on Tuesday, as the group is closely tied to the pace of global economic growth. Morgan Stanley was one of the top percentage losers on the S&P on Monday, dropping more than 6 percent on concerns about the company's exposure to European debt.


Dow component Home Depot Inc will also be in focus after the home improvement retailer reported adjusted earnings and sales that beat expectations. Home Depot was up 1.3 percent to $64.75 in premarket trading.


S&P 500 futures rose 2.6 points and were above fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract. Dow Jones industrial average futures added 49 points and Nasdaq 100 futures rose 3.25 points.


In the S&P, the 1,500 will be watched as a key level after the index closed below it on Monday for the first time since February 4, with selling accelerating after falling below the level that had acted as support. An inability to break back above it could portend a weaker technical backdrop. The index remains 4.3 percent higher on the year.


Gains this year have largely been driven by strong corporate earnings. With 83 percent of the S&P 500 having reported so far, 69 percent beat profit expectations, compared with a 62 percent average since 1994 and 65 percent over the past four quarters, according to Thomson Reuters data. Fourth-quarter S&P earnings are seen having risen 6 percent, above a 1.9 percent forecast at the start of the earnings season.


Companies scheduled to report results on Tuesday include Macy's Inc , Priceline.com and Tenet Healthcare . MetroPCS reported revenue that was slightly ahead of expectations earlier Tuesday.


Cyclical shares, including financials and materials, have been among the strongest performers in 2013, lifted by signs of improved economic growth. That could leave the sectors vulnerable to a pullback as events in Italy progress. Goldman Sachs on Tuesday cut its 2013 gold price forecast to $1,600 an ounce from $1,810, citing an increase in U.S. real interest rates.


While the political uncertainty from Italy may be the primary driver for markets, domestic government concerns will also be in focus. U.S. equities will face a test with the looming debate over so-called sequestration - U.S. government budget cuts that will take effect starting on Friday if lawmakers fail to reach an agreement over spending and taxes. The White House issued warnings about the harm the cuts are likely to inflict on the economy if enacted.


(Editing by Chizu Nomiyama)



Read More..

LG aims to raise smartphone sales by 52 percent






SEOUL, South Korea (AP) — LG Electronics Inc. is aiming to raise its smartphone sales by more than half this year as it makes a shift from basic phones to high-end devices after lagging competitors for several years.


The South Korean company aims to sell more than 40 million smartphones in 2013, it said in a statement on Monday. LG shipped 26.3 million smartphones in 2012, fewer than HTC Corp. and Research In Motion Ltd. which each shipped more than 32 million smartphones.






To meet the sales goal, LG will release handsets in all price ranges from high-tier to affordable models and go all out in both developed and emerging markets.


“We aim to improve profitability and also to become a top-tier smartphone brand,” Park Jong-seok, head of LG’s mobile phone business, told reporters at a mobile industry fair in Barcelona, according to the statement.


LG faces similar challenges to other second-tier smartphone vendors. They are squeezed by the two smartphone giants — Samsung Electronics Co. and Apple Inc. — that are dominating most of the profit in the smartphone industry and also by Chinese makers that are expanding in the smartphone markets of fast-growing emerging countries.


But LG hopes to make its Optimus brand stand out by drawing on technologies from other parts of the LG empire. The company is the largest shareholder in LG Display Co. and has collaborated with other LG affiliates on batteries and cameras.


LG was the world’s third-largest maker of cellphones in 2009 but was caught off guard by the popularity of smartphones. In the fourth quarter of 2012, LG sold fewer phones than Chinese rivals Huawei Technologies Ltd. and ZTE Corp., which are expanding shipments of their cheaper smartphones.


Its mobile communications division was profitable for the first time in three years last year as it moved its focus from basic phones to lucrative smartphones.


Wireless News Headlines – Yahoo! News





Title Post: LG aims to raise smartphone sales by 52 percent
Url Post: http://www.news.fluser.com/lg-aims-to-raise-smartphone-sales-by-52-percent/
Link To Post : LG aims to raise smartphone sales by 52 percent
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Stock futures advance, Barnes & Noble up early

NEW YORK (Reuters) - Stock index futures rose on Monday, suggesting the recent rally for equities remains intact in spite of concerns that the U.S. Federal Reserve could curtail its stimulus sooner than many expected.


* Stocks have been strong performers so far this year, with the S&P 500 jumping 6.2 percent in 2013. Pullbacks have generally been slight, with investors using any dip as a buying opportunity. While the S&P fell last week, the decline was a slight 0.3 percent and it was the first weekly drop after a seven-week streak of gains.


* The gains have come on strong corporate earnings, as well as a backdrop of stimulus from the Federal Reserve. Last week's decline came when some Fed officials seemed to suggest the stimulus may be curtailed faster than many expected, though subsequent comments seemed to allay those concerns.


* Another test for equities will come with the looming debate over massive U.S. government budget cuts that will take effect if lawmakers fail to reach an agreement over spending and taxes. On Sunday, the White House issued more dire warnings about the harm the cuts are expected to do to the economy if enacted.


* More government-related uncertainty came from Italy, where a close election left questions about how the country would handle its three-year debt crisis. Last year, inconclusive Greek elections sparked a protracted selloff and a period of uncertainty in U.S. equity markets as well.


* Still, European shares <.fteu3> were higher on Monday, rising 0.6 percent after a smooth Italian debt auction.


* S&P 500 futures rose 6.4 points and were above fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract. Dow Jones industrial average futures added 39 points and Nasdaq 100 futures rose 17.25 points.


* In company news, the Wall Street Journal reported that Barnes & Noble Inc Chairman Leonard Riggio is considering a bid for the company's bookstore business. The stock jumped 18 percent to $16 in premarket trading.


* Lowe's Cos Inc reported earnings that beat expectations, helped by rebuilding efforts after Hurricane Sandy in the United States.


* Other companies scheduled to report quarterly results include Autodesk Inc and FirstEnergy .


* Fourth-quarter earnings for S&P 500 companies are estimated to have risen 6 percent, according to Thomson Reuters data, above a 1.9 percent forecast at the start of the earnings season.


* U.S. stocks closed higher on Friday, boosted by strong results from Hewlett-Packard Co , as well as allayed concerns over Fed policy.


(Editing by Chizu Nomiyama)



Read More..

Samsung sets sights on iPad mini with new Galaxy Note 8.0 tablet






Samsung (005930) is finally gaining some momentum in the tablet market after a slow start with the original Galaxy Tab, which launched in late 2010. The South Korean consumer electronics giant now has a number of slates available in the 7- and 10-inch ranges, but Apple’s (AAPL) 8-inch iPad mini opened new doors for mid-size tablets following its release this past November. Samsung was already putting a mid-range tablet together when the iPad mini debuted last year, and now the company is finally ready to take the wraps off its latest Note series device: The Galaxy Note 8.0.


[More from BGR: BlackBerry 10 browser smokes iOS 6 and Windows Phone 8 in comparison test [video]]






With a footprint that measures 8.3 inches by 5.4 inches, the Galaxy Note 8.0 can be used comfortably with one hand but provides much more screen real estate than a 7-inch tablet. As this slate falls into Samsung’s Note lineup, it also includes an S Pen stylus and an updated suite of stylus-ready apps.


[More from BGR: The end of unlimited BBM could erode BlackBerry’s standing in emerging markets]


Samsung’s new 8-inch Note slides perfectly into the gap between the Galaxy Note II and the Galaxy Note 10.1. “It’s the best of both worlds,” Samsung Mobile’s director of product planning Shoneel Kolhatkar said during a briefing.


Key specs include an 8-inch 1280 x 800-pixel TFT display, a 1.6GHz quad-core processor, 2GB of RAM, 32GB or 64GB of internal storage, microSDXC support, a 4,600 mAh battery, Android 4.1.2 Jelly Bean and a sleek case that is 25% thinner that the Galaxy Note 10.1. The Note 8.0 also includes an integrated 3G antenna, but a Wi-Fi-only version will be available shortly after the 3G version launches.


While Samsung focused mainly on the consumer market with the first Galaxy Note tablet, The Note 8.0 is as much about enterprise as it is about consumers. ”The next big thing is being extended to business,” Samsung Electronics’ marketing boss Travis Merrill told reporters at a recent meeting in New York City. Great features like the ability to run multiple apps at once in different windows extends the slate’s utility in a business environment, and Samsung’s “SAFE” certification means the tablet is secure.


Other intriguing features include a new “Readers Mode,” which conserves battery, dims the screen and changes the tablet’s contrast settings to make it a great eReader, and a host of new second screen features that make the Note 8.0 a solid TV companion.


The Galaxy Note 8.0 will launch in a number of markets around the world including the United States beginning in the second quarter this year. Pricing has not yet been announced.


Samsung’s full press release follows below, and be sure to check out our hands-on impressions of Samsung’s new Galaxy Note 8.0 tablet.



INTRODUCING THE GALAXY NOTE 8.0,
A NEW ERA OF PORTABILITY AND EVERYDAY PRODUCTIVITY


SEOUL, Korea [February 24, 2011] – Samsung Electronics Co., Ltd, a global leader in digital media and digital convergence technologies, today announced the launch of the 8 inch tablet, the GALAXY Note 8.0; a new era of intelligent Note technology set to re-ignite the mid-size tablet category that Samsung established in 2010. Providing unrivalled multimedia performance within a compact one-hand-grip screen, the GALAXY Note 8.0 has the power and advanced technology to evolve the tablet experience and ensure you achieve new levels of efficient multi-tasking while benefitting from superb voice call functionality*. Furthermore, the intelligent S Pen brings together the latest innovation and the ease of using a traditional pen and paper; creating a sophisticated mobile experience that will enhance life on the go.


“Back in 2010 the launch of the first Samsung GALAXY Tab with 7 inch screen opened a new chapter in the mobile industry. Now almost three years later, Samsung continues to evolve the sector that meets the demands of modern life.” said JK Shin, President of the IT & Mobile Communications Division at Samsung Electronics.


“The GALAXY Note 8.0 breaths fresh life into the category as it delivers the perfect fusion of portability and everyday productivity – the result is a pioneering, pocket-sized solution that enhances and enriches our everyday lives, whether at work or play,” added Shin.


At the core of the GALAXY Note 8.0’s innovative solutions are beneficial functions, including multi-window options to split the portable 8inch screen and allow optimal access to a number of live applications; a new generation of Samsung’s intelligent S Pen with advanced usability; access to a suite of S Note templates and tools that allow you to create, edit, manage and share everyday documents; the Samsung “reading mode” technology to enjoy e books with optimized resolution, video and voice calls*. In addition, a suite of exciting new content and services are pre-loaded for users at no additional cost including, for the very first time on Samsung GALAXY tablet, the innovative Flipboard, and Awesome Note.


A smart diary for life on the go


Slim and compact enough to become the perfect on-the-go work and play companion, the GALAXY Note 8.0 brings powerful performance and functionality to support even the most demanding of lifestyles. Designed to store and manage your personal and professional data efficiently, the new era device gives users the perfect pocket-sized hands-on organizational tool. Practical S Note templates and S Planner feature help to manage everyday tasks, including meeting notes, to-do lists and even personal diary entries. All content can be entered and updated with the finest of detail thanks to the evolution of the intelligent Samsung S Pen. Enhanced precision is offered with Handwriting-to-Text conversion and advanced Productivity Tools that support formula and shape recognition are now available at the touch of your S Pen.


New content and services


GALAXY Note 8.0 is packed with pre-loaded content and apps specifically for the value maximizing, mass multimedia consumer. Upgraded Chat-On provides easy instant messaging and group chatting in multiple formats – images, video, voice, contacts – for simple, enjoyable communication. Awesome Note, an integrated application that is introduced in android tablet for the first time with NOTE 8.0, is capable of unlimited note-taking uses including Memo, Diary and Must-remember lists. With Flipboard, your news, social network and other feeds come together in one stylish, flippable format so you can enjoy all your news and life’s great moments in one place. Flipboard developed a customized version of its application exclusively for Samsung that allows users to take the S Pen’s hover feature and preview article headers beneath Flipboard’s main screen tiles. Finally, Smart Remote, gives you a universal remote control and electronic programming guide allowing you to manage TV and video watching seamlessly.


A new age of S Pen intelligence


Optimized to aid personalized creativity, the Samsung S Pen has evolved to increase everyday usability and enhance creation expression. Embedded within the tablet, the S Pen is an extension of the GALAXY Note 8.0. Removing the S Pen from the device will automatically launch innovative features such as Pen Detection that will suggest adapted menus that it thinks you’ll need and Page Buddy, a feature that will intuitively activate your most recently adapted S Note home screen.


S Pen technology is now so advanced that it doesn’t even have to touch the screen. With Air View, the S Pen needs only to hover over the screen to see previews of videos, emails, photos and appointments on SPlanner without opening the file or application in full. S Pen Gesture allows images and content to be easily edited and cropped, whilst Paper Artist and Photo Note allow photos to be artistically personalized.


In addition, for the very first time in GALAXY NOTE category, you can use S Pen to control the physical menu/back buttons on the device with WACOM technology.


Maximizing mass multimedia consumption


Creative multi-tasking with the GALAXY Note 8.0 is effortless due to innovative Dual View feature, two multi window options that seamlessly allow you to facilitate multi-screen usage. Dual View’s split screen accommodates optimal operation of different apps, such as launching the S Note on the web browser screen and allowing content to be resized, dragged and dropped as required.


Multi-tasking is extended to phone calls*. Pop Up Note allows you to access S Note at any time to keep track of key actions and Pop Up Video ensures you can keep surfing the web whilst chatting – content windows can be easily resized by pinching to enlarge or reduce.


Perfect info-tainment partner


Packed with features to engage, entertain and excite, the GALAXY Note 8.0 supports your practical everyday needs. Reading Mode transforms the GALAXY Note 8.0 into an e-Book reader, provides the optimal reading conditions to ensure you can curl up and enjoy a good book. You can even turn it into a universal remote control with Smart Remote, to seamlessly manage TVs, set-up boxes, DVD & Blu-ray players.



This article was originally published on BGR.com


Gadgets News Headlines – Yahoo! News





Title Post: Samsung sets sights on iPad mini with new Galaxy Note 8.0 tablet
Url Post: http://www.news.fluser.com/samsung-sets-sights-on-ipad-mini-with-new-galaxy-note-8-0-tablet/
Link To Post : Samsung sets sights on iPad mini with new Galaxy Note 8.0 tablet
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

See the Mini Balenciaga Bag Kim Kardashian Gifted Niece Penelope




Celebrity Baby Blog





02/22/2013 at 05:00 PM ET



Mom Kourtney Kardashian has one! Aunts Kim and Khloé own one too. And now Penelope Disick is the latest family member to add Balenciaga‘s chic city tote to her closet.


“Penelope is wearing the little Balenciaga bag that I got her for Christmas!” Kim posted on Instagram Friday, along with an adorable photo of the mom-to-be with her 7½-month-old niece and her mini yellow handbag.


Is Kim gearing up for her little one? If she has a little girl, we have no doubt her wardrobe will be the envy of the playground. Although the expectant reality star recently revealed that if it’s up to dad-to-be Kanye West, their baby will be wearing lots of “big chains and leather pants.”


And to be fair, Penelope wasn’t the only Kardashian-Jenner kid to receive luxe fashions for Christmas. Kylie and Kendall also scored during the holidays.


Kim Kardashian, Penelope Disick and Her Mini Balenciaga Bag
Courtesy Kim Kardashian; Inset: Rex USA



– Shanelle Rein-Olowokere


Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..